Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria
CONCLUSIONS: Quality of life scores and the depression level are improved in RRMS patients treated with fingolimod over 2 years in real-life setting.PMID:38018696 | DOI:10.33588/rn.77s04.2023213 (Source: Revista de Neurologia)
Source: Revista de Neurologia - November 29, 2023 Category: Neurology Authors: I Milanov S Ivanova I Tournev T Chamova A Kaprelyan G Slavov V Chervenkov K Kipriyanovska Source Type: research
Bioavailable central nervous system disease-modifying therapies for multiple sclerosis
Disease-modifying therapies for relapsing multiple sclerosis reduce relapse rates by suppressing peripheral immune cells but have limited efficacy in progressive forms of the disease where cells in the central nervous system play a critical role. To our knowledge, alemtuzumab, fumarates (dimethyl, diroximel, and monomethyl), glatiramer acetates, interferons, mitoxantrone, natalizumab, ocrelizumab, ofatumumab, and teriflunomide are either limited to the periphery or insufficiently studied to confirm direct central nervous system effects in participants with multiple sclerosis. In contrast, cladribine and sphingosine 1-phosp...
Source: Frontiers in Immunology - November 29, 2023 Category: Allergy & Immunology Source Type: research
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis —Variations in Real-World Experience—Reply
In Reply We thank Dr Wolf and colleagues for highlighting the importance of clinical context when evaluating effectiveness of multiple sclerosis (MS) therapies. As demonstrated in the comparative effectiveness of natalizumab and fingolimod, where seemingly discordant results emerged from different registries, characteristics of the study population play a central role in study findings. It is, therefore, important to differentiate between studies of treatment efficacy and effectiveness. (Source: JAMA Neurology)
Source: JAMA Neurology - November 20, 2023 Category: Neurology Source Type: research
Beneficial Effect of Fingolimod in a Lafora Disease Mouse Model by Preventing Reactive Astrogliosis-Derived Neuroinflammation and Brain Infiltration of T-lymphocytes
AbstractLafora disease (LD; OMIM#254780) is a rare, devastating, and fatal form of progressive myoclonus epilepsy that affects young adolescents and has no treatment yet. One of the hallmarks of the disease is the accumulation of aberrant poorly branched forms of glycogen (polyglucosans, PGs) in the brain and peripheral tissues. The current hypothesis is that this accumulation is causative of the pathophysiology of the disease. Another hallmark of LD is the presence of neuroinflammation. We have recently reported the presence of reactive glia-derived neuroinflammation in LD mouse models and defined the main inflammatory pa...
Source: Molecular Neurobiology - November 16, 2023 Category: Neurology Source Type: research
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
Conclusions
The effectiveness of natalizumab and fingolimod in active RRMS is superior to dimethyl fumarate, teriflunomide, glatiramer acetate and interferon beta. This study demonstrates the utility of MSM in emulating trials to compare clinical effectiveness among multiple interventions simultaneously. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 15, 2023 Category: Neurosurgery Authors: Diouf, I., Malpas, C. B., Sharmin, S., Roos, I., Horakova, D., Kubala Havrdova, E., Patti, F., Shaygannejad, V., Ozakbas, S., Eichau, S., Onofrj, M., Lugaresi, A., Alroughani, R., Prat, A., Duquette, P., Terzi, M., Boz, C., Grand'Maison, F., Sola, P., Fer Tags: Editor's choice Multiple sclerosis Source Type: research
Study of fingolimod, nitric oxide inhibitor, and P-glycoprotein inhibitor in modulating the P-glycoprotein expression via an endothelin & #8211;sphingolipid pathway in an animal model of pharmacoresistant epilepsy
CONCLUSION: The modulation of the P-gp expression by Fingolimod improved drug delivery to the brain in an animal model of refractory epilepsy. Therefore, S1P signaling could serve as an additional therapeutic target to overcome refractoriness. (Source: Indian Journal of Pharmacology)
Source: Indian Journal of Pharmacology - November 2, 2023 Category: Drugs & Pharmacology Authors: Nitika Garg Rupa Joshi Alka Bhatia Seema Bansal Amitava Chakrabarti Ajay Prakash Biman Saikia Manish Modi Bikash Medhi Source Type: research
Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod
(Source: Journal of Neurology)
Source: Journal of Neurology - November 1, 2023 Category: Neurology Source Type: research
Graves ’ Orbitopathy Models: Valuable Tools for Exploring
Pathogenesis and Treatment
Horm Metab Res 2023; 55: 745-751 DOI: 10.1055/a-2161-5417Graves’ orbitopathy (GO) is the most common extrathyroidal complication
of Graves’ disease (GD) and severely affects quality of life. However,
its pathogenesis is still poorly understood, and therapeutic options are
limited. Animal models are important tools for preclinical research. The animals
in some previous models only exhibited symptoms of hyperthyroidism without
ocular lesions. With the improvements achieved in modeling methods, some
progressive animal models have been established. Immunization of...
Source: Hormone and Metabolic Research - October 30, 2023 Category: Endocrinology Authors: Wang, Ling Zhang, Meng Wang, Yue Shi, Bingyin Tags: Review Source Type: research
Effects of Crocin on brain neurotrophins, cognition, balance and pain in toxic-induced demyelination model
CONCLUSION: Based on the current findings, crocin can improve the level of brain neurotrophins, exploratory behavior, balance and pain after toxin-demyelination as close as fingolimod results.PMID:37848220 (Source: Acta Neurologica Taiwanica)
Source: Acta Neurologica Taiwanica - October 17, 2023 Category: Neurology Authors: Rouholah Fatemi Hadi Fathi Moghaddam Yaghoub Farbod Roya Beygtashkhanib Source Type: research
The effect of glatiramer acetate, IFN β-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients
This study investigates gene expression profiles of T-box transcription factor TBX21 (T-bet), interferon-gamma (IFN-γ), and long non-coding RNA MEG3 in peripheral blood mononuclear cells (PBMCs) from treatment-naïve Relapsing-Remitting Multiple Sclerosis patients (RRMS), healthy controls, and RRMS patients on different Disease Modifying Therapies (DMTs). The aim is to understand the role of T-bet, IFN-γ, and MEG3 in MS pathogenesis and their potential as diagnostic and therapeutic targets.RESULTS: Elevated T-bet expression is observed in treatment-naïve RRMS patients compared to healthy individuals. RRMS patients treat...
Source: Cell Research - October 16, 2023 Category: Cytology Authors: Rozhin Dabbaghi Reza Safaralizadeh Shima Rahmani Nesa Barpour Mohammadali Hosseinpourfeizi Ali Rajabi Behzad Baradaran Source Type: research
The effect of glatiramer acetate, IFN β-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients
This study investigates gene expression profiles of T-box transcription... (Source: BMC Research Notes)
Source: BMC Research Notes - October 16, 2023 Category: Research Authors: Rozhin Dabbaghi, Reza Safaralizadeh, Shima Rahmani, Nesa Barpour, Mohammadali Hosseinpourfeizi, Ali Rajabi and Behzad Baradaran Tags: Research Note Source Type: research
Multiple Sclerosis, Disease-Modifying Therapies, and Infections
Discussion
Patients with MS have higher risks of outpatient and serious infections compared with patients without MS. The risk of outpatient infections was similarly increased by rituximab and fingolimod and serious infections by rituximab and natalizumab compared with IFN/GLAT. Steps to minimize risks include optimizing bladder care, comorbidity prevention, varicella vaccination, and considering discontinuing or avoiding DMT use in patients with advanced disability and/or previous hospitalizations for infections. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - October 9, 2023 Category: Neurology Authors: Langer-Gould, A. M., Smith, J. B., Gonzales, E. G., Piehl, F., Li, B. H. Tags: Multiple sclerosis Research Article Source Type: research
Cryptococcal meningoencephalitis in multiple sclerosis treated with fingolimod
Pract Neurol. 2023 Oct 6:pn-2023-003691. doi: 10.1136/pn-2023-003691. Online ahead of print.ABSTRACTA 21-year-old woman with multiple sclerosis (taking regular fingolimod) developed sudden-onset severe headache with nausea and malaise. Neurological examination was normal and she was afebrile. Blood results showed lymphocytes 0.53 x 109/L and C reactive protein 19 mg/L. CT scan of head and venogram were normal. CSF showed an opening pressure of 33 cm H2O and an incidental light growth of Cryptococcus neoformans, confirmed with positive India Ink stain and a positive cryptococcal antigen (1:100). She was treated for cryptoco...
Source: Practical Neurology - October 6, 2023 Category: Neurology Authors: Moneeb Nasir Ian Galea Aidan Neligan Karen Chung Source Type: research
Cryptococcal meningoencephalitis in multiple sclerosis treated with fingolimod
Pract Neurol. 2023 Oct 6:pn-2023-003691. doi: 10.1136/pn-2023-003691. Online ahead of print.ABSTRACTA 21-year-old woman with multiple sclerosis (taking regular fingolimod) developed sudden-onset severe headache with nausea and malaise. Neurological examination was normal and she was afebrile. Blood results showed lymphocytes 0.53 x 109/L and C reactive protein 19 mg/L. CT scan of head and venogram were normal. CSF showed an opening pressure of 33 cm H2O and an incidental light growth of Cryptococcus neoformans, confirmed with positive India Ink stain and a positive cryptococcal antigen (1:100). She was treated for cryptoco...
Source: Practical Neurology - October 6, 2023 Category: Neurology Authors: Moneeb Nasir Ian Galea Aidan Neligan Karen Chung Source Type: research
